PMID- 32533547
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 11
IP  - 8
DP  - 2020 Aug
TI  - Understanding Reasons for Treatment Discontinuation, Attitudes and Education 
      Needs Among People Who Discontinue Type 2 Diabetes Treatment: Results from an 
      Online Patient Survey in the USA and UK.
PG  - 1873-1881
LID - 10.1007/s13300-020-00843-9 [doi]
AB  - INTRODUCTION: Type 2 diabetes mellitus (T2DM) requires long-term treatment to 
      achieve and maintain glycaemic control; however, up to 50% of people with T2DM 
      discontinue treatment by 1 year. It is therefore important to understand the 
      patient perspective of therapeutic adherence and persistence. METHODS: An online 
      questionnaire was presented to people with T2DM in the USA and UK on 
      PatientLive((R)), a platform of Carenity, an online patient community. Those who 
      discontinued at least one T2DM treatment within the last 6 months answered 
      open-ended questions aimed to assess the reasons for discontinuation, how 
      discontinuation could have been prevented, and what would have improved the 
      experience with the discontinued treatment. Thematic qualitative analysis was 
      performed on respondents' answers to these questions. RESULTS: Oral antidiabetics 
      were the most commonly discontinued treatments (93/161), followed by insulin 
      (40/161) and glucagon-like peptide 1 receptor agonists (13/161). Main reasons for 
      treatment discontinuation overall were side effects (57/161), mostly 
      gastrointestinal side effects and weight gain. The second most reported reason 
      was drug efficacy issues (42/161). Key factors stated to prevent discontinuation 
      were an improved care pathway (45/161) and more efficacious treatments with fewer 
      side effects (41/161). In the USA, treatment cost played an important role in 
      discontinuation (14/89) and discontinuation prevention (12/89). More information 
      about T2DM and associated treatments (56/161), help with T2DM management 
      (24/161), and increased and informative patient-physician interaction (12/161) 
      would have been helpful for many respondents in both countries, while some 
      patients noted that no additional information would have been useful to improve 
      their understanding and experience with their T2DM treatment (64/161). 
      CONCLUSIONS: These results emphasise the need for focused medical education and 
      improved communication to enhance patient experience and prevent treatment 
      discontinuation. Understanding of attributes preferred by people with T2DM can 
      help improve therapeutic adherence and outcomes with current medications, and 
      guide development of future therapies.
FAU - Roborel de Climens, Aude
AU  - Roborel de Climens A
AD  - Sanofi, Lyon, France. aude.roborel-de-climens@sanofi.com.
FAU - Pain, Emilie
AU  - Pain E
AD  - Carenity, Paris, France.
FAU - Boss, Anders
AU  - Boss A
AD  - Sanofi, Bridgewater, NJ, USA.
FAU - Shaunik, Alka
AU  - Shaunik A
AD  - Sanofi, Bridgewater, NJ, USA.
LA  - eng
PT  - Journal Article
DEP - 20200612
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC7376801
OTO - NOTNLM
OT  - Discontinuation
OT  - Injectable: insulin
OT  - Oral
OT  - Survey
OT  - Treatment
OT  - Type 2 diabetes
EDAT- 2020/06/14 06:00
MHDA- 2020/06/14 06:01
PMCR- 2020/06/12
CRDT- 2020/06/14 06:00
PHST- 2020/04/24 00:00 [received]
PHST- 2020/06/14 06:00 [pubmed]
PHST- 2020/06/14 06:01 [medline]
PHST- 2020/06/14 06:00 [entrez]
PHST- 2020/06/12 00:00 [pmc-release]
AID - 10.1007/s13300-020-00843-9 [pii]
AID - 843 [pii]
AID - 10.1007/s13300-020-00843-9 [doi]
PST - ppublish
SO  - Diabetes Ther. 2020 Aug;11(8):1873-1881. doi: 10.1007/s13300-020-00843-9. Epub 
      2020 Jun 12.